Drug – bio-affecting and body treating compositions – Enzyme or coenzyme containing – Hydrolases
Reexamination Certificate
2005-07-26
2005-07-26
Page, Thurman K. (Department: 1616)
Drug, bio-affecting and body treating compositions
Enzyme or coenzyme containing
Hydrolases
C424S094100, C514S002600, C514S169000
Reexamination Certificate
active
06921532
ABSTRACT:
The present invention relates generally to the preparation and use of biological tissue adhesives which rely on combining fibrinogen and thrombin. More particularly, the present invention relates to a method of preparing a fibrin sealant whereby said sealant is formed by reconstituting the fibrinogen or the thrombin component in the presence of biological and/or non-biological agents such as drugs, chemicals, and proteins. Preferably, these agents are introduced in solution, such as for example, a corticosteroid-containing solution like a betamethasone solution containing betamethasone acetate or betamethasone sodium phosphate; a triamicinolone solution; or a methylprednisolone solution. These solutions may be substituted for, or provided as a complement to, other solutions that are typically used in the preparation of fibrin sealants such as, for example, calcium chloride. The invention further relates to a novel method of using the improved fibrin sealant whereby the sealant and accompanying agent(s) are delivered directly to a critical site within the body and sealed in place due to the bio-static quality of the sealant. This provides therapeutic value to patients through prolonged presence, and optionally time-released delivery, of the specific agent(s) at the critical site.
REFERENCES:
patent: 2533004 (1950-12-01), Ferry et al.
patent: 3089815 (1963-05-01), Lieb et al.
patent: 4359049 (1982-11-01), Redl et al.
patent: 4393041 (1983-07-01), Brown et al.
patent: 4427650 (1984-01-01), Stroetmann
patent: 4442655 (1984-04-01), Stroetmann
patent: 4619913 (1986-10-01), Luck et al.
patent: RE33375 (1990-10-01), Luck et al.
patent: 5124155 (1992-06-01), Reich
patent: 5264446 (1993-11-01), Hegasy et al.
patent: 5290552 (1994-03-01), Sierra et al.
patent: 5643192 (1997-07-01), Hirsh et al.
patent: 5651982 (1997-07-01), Marx
patent: 5702715 (1997-12-01), Nikolaychik et al.
patent: 5925738 (1999-07-01), Miekka et al.
patent: 5962420 (1999-10-01), Edwardson et al.
patent: 5980504 (1999-11-01), Sharkey et al.
patent: 5980866 (1999-11-01), Uchida et al.
patent: 6007570 (1999-12-01), Sharkey et al.
patent: 6007811 (1999-12-01), Sawyer et al.
patent: 6054122 (2000-04-01), MacPhee et al.
patent: 6073051 (2000-06-01), Sharkey et al.
patent: 6117425 (2000-09-01), MacPhee et al.
patent: 6122549 (2000-09-01), Sharkey et al.
patent: 6124273 (2000-09-01), Drohan et al.
patent: 6126682 (2000-10-01), Sharkey et al.
patent: 6183518 (2001-02-01), Ross et al.
patent: 6197325 (2001-03-01), MacPhee et al.
patent: 6258086 (2001-07-01), Ashley et al.
patent: 6261311 (2001-07-01), Sharkey et al.
patent: 6320029 (2001-11-01), Miekka et al.
patent: 6428576 (2002-08-01), Haldimann
patent: 6468527 (2002-10-01), Austin et al.
patent: 6517568 (2003-02-01), Sharkey et al.
patent: 6547810 (2003-04-01), Sharkey et al.
patent: 6638276 (2003-04-01), Sharkey et al.
patent: 6559119 (2003-05-01), Burgess et al.
patent: RE38431 (2004-02-01), Miekka et al.
patent: 6726685 (2004-04-01), To et al.
patent: 6733496 (2004-05-01), Sharkey et al.
patent: 6749605 (2004-06-01), Ashley et al.
patent: 6762336 (2004-07-01), MacPhee et al.
patent: 6767347 (2004-07-01), Sharkey et al.
patent: 2003/0181964 (2003-09-01), Sharkey et al.
patent: 2004/0111136 (2004-06-01), Sharkey et al.
patent: 2004/0193151 (2004-09-01), To et al.
patent: 3037270 (1982-05-01), None
patent: 0 068 149 (1982-05-01), None
patent: WO 81/00516 (1981-05-01), None
patent: WO92/22312 (1992-12-01), None
patent: WO 94/20133 (1994-09-01), None
patent: WO 96/17633 (1996-03-01), None
patent: WO97/42986 (1997-11-01), None
US 6,645,204, 11/2003, Sharkey et al. (withdrawn)
Abstract: Yagita, T.,Agent for Controlling Formation of Cheloid at Excision Site for Inflammation Bowel Disease. . . ,Database WPI, Section Ch, Week 199716, Derwent Publications Ltd., London, GB XP002182938, Feb. 10, 1997.
Abstract: Sumitomo Cement Co.,Sustained Release Agent for Treatment of Osteomyelitis. . . , Database WPI, Section Ch, Week 199306, Derwent Publications Ltd., London, GB XP002182939, Jan. 8, 1993.
J. Rousou, et al., “Randomized Clinical Trial of Fibrin Sealant in Cardiac Surgery Patients Undergoing Resternotomy . . .”,Journal of Thoracic and Cardiovascular Surgery,vol. 97, No. 2, pp 194-203, Feb. 1989.
P. Knoringer, “Fibrin Sealing in Spinal Neurosugery”, 1986.
P. M. McCarthy, et al., “Fabrin Sealant: The Cleveland Clinic Experience”, 1991.
M. Dahan et al., “The Importance of Biological Glue for the Prevention of Air Leakage in Pulmonary Sugery”,Materials and Methods,pp 113-116, 1991.
H.W. Walclawiczek, “Fibrin Sealing in Liver and Spleen Sugery”, 1994.
C. Shaffrey, et al., “Neurosurgical Applications of Fibrin Glue: Augmentation of Dural Closure in 134 Patients”,Neurosurgery, vol. 26, No.2, pp 207-210, 1990.
M. Acqui, R. Delfini, A. Raco, and L. Ferrante, “Our Experience with Human Fibrin Glue in Neurosurgical Procedures”, date unknown.
Allan Hjortrup, M.D., Flemming Moesgaard, M.D., Ph.D., Johan Kjaergard, M.D., Ph.D, “Fibrin Adhesive in Perineal Fistulas”, from the Dept of Surgical Gastroenterology F, Bispebjerg Hospital and Dept of Surgical Gastroenterology C, Rigsbospitalet, University of Copenhagen, Copenhagen, Denmark, vol. 34. No. 9, Sep. 1991.
T.M. Kieser, A. Maitland, L. Parsons, L. Davison, and R.C. Woodman, “Reduced Postoperative Bleeding Following Use of Tisseel Fibrin Sealant in 300 Patients Undergoing Open-Heart Surgery”, date unknown.
William D. Spotnitz, M.D., and Rosanne L. Welker, Ph.D, “Clinical Uses of Fabrin Sealant”,Tranfusion Therapy: Clinical Principles and Practice,Bethesda, MD: AABB Press, 1999.
N. Tajima, S. Kuwahara, S. Hirakawa, and K. Matsumoto, “Bone Grafts Using Fibrin Glue for Posterolateral Spinal Fusion and Total Hip Replacement with Central Migration”, date unknown.
Bong Gyu Yu, et al., “Development of a local antibiotic delivery system using fibrin glue”,Journal of Controlled Release,39, pp 65-70 (1996).
Gregory E. Lutz, M.D., Vijay B. Vad, M.D., and Ronald J. Wisneski, M.D., “Flourscopic Transforaminal Lumbar Epidural Steroids: An Outcome Study”,Arch Phys Med Rehabil,Vol 79, pp 18-21, Nov. 1998.
Goupille P, Jayson MI, Valat JP, Freemont AJ, “The Role of Inflammation in Disk Herniation-Associated Radiculopathy”,Semin Arthritis Rheum,1998, Aug. 28 (1):60-71.
Kang JD, Georgeescu HI, McIntyre-Larkin L, Stefanovic-Racic M, Donaldson WF 3rd, Evans CH, “Herinated Lumbar Intervertebral Disc Spontaneously Produce Matrix Metalloproteinases, Nitric Oxide, Interleukin-6, and Prostaglandin E2”,Spine1996 Feb 1; 21(3);271-70.
Saal JS, Franson RC, Dobrow R, Saal JA, White AH, Goldthwaite N, “High Levels of Inflammatory Phospholipase A2 Activity in Lumbar Disc Herniations”,Spine1990 Jul; 15 (7):674-8.
Nygaard OP, Mellgren SI, Osterud B, “The Inflammatory Properties of Contained and Noncontained Lumbar Disc Herniation”,SpineNov 1 1997;22(21):2484-88.
Takahashi H, Suguro T, Okazima Y, Motegi M, Okada Y, Kakiuchi T, “Inflammatory Cytokines in the Herniated Disc of the Lumbar Spine”,SpineJan 15 1996;21(2):218-24.
Product Information, Celestone Soluspan, brand of betamethasone sodium phosphate and betamethasone acetate Injectable Suspension, USP 6 mg per mL, Schering Corporation, Kenilworth, NJ 07033 USA, Rev. Mar. 1996.
Product Information,Fibrin Sealant Hemaseel APR Kit, Two-Component Fibrin Sealant, Vapor Heated, Kit,Manufactured for and Distributed by Haemacure Corp., 2 N. Tamiami Trail, Ste. 802, Sarasota, FL. 34236, Issued May 1998.
Austin Sam L.
Davis Thomas E.
George Konata M.
O'Keefe, Egan & Peterman
Page Thurman K.
Spinal Restoration, Inc.
LandOfFree
Biological Bioadhesive composition and methods of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Biological Bioadhesive composition and methods of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biological Bioadhesive composition and methods of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3423644